Literature DB >> 2551973

Latent and replicating forms of Epstein-Barr virus DNA in lymphomas and lymphoproliferative diseases.

B Z Katz1, N Raab-Traub, G Miller.   

Abstract

Epstein-Barr virus (EBV) is associated with lymphomas and lymphoproliferative diseases that occur mainly in immunocompromised patients, but the role EBV plays in their pathogenesis is unclear. The evidence linking EBV etiologically to these disorders includes the presence of EBV DNA and nuclear antigens in the lesions and serologic evidence that some patients with these lesions are experiencing primary or reactivated EBV infections. These syndromes may represent proliferation of cells latently infected with EBV, but the possibility of viral replication has not been rigorously studied. DNA extracted from biopsies of 35 lymphoproliferative diseases was probed with regions of the EBV genome capable of distinguishing circular, episomal DNA found in latency from linear, replicating EBV DNA. All samples contained restriction fragments characteristic of fused termini, indicative of circular, latent genomes. Thirteen samples contained additional restriction fragments diagnostic of linear EBV DNA. Therefore, replicating EBV DNA is found in approximately 40% of EBV-associated lymphoproliferative disorders.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2551973     DOI: 10.1093/infdis/160.4.589

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  48 in total

1.  Phosphorylation of the Epstein-Barr virus (EBV) DNA polymerase processivity factor EA-D by the EBV-encoded protein kinase and effects of the L-riboside benzimidazole 1263W94.

Authors:  Edward Gershburg; Joseph S Pagano
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

2.  Epstein-Barr and human immunodeficiency viruses in acquired immunodeficiency syndrome-related primary central nervous system lymphoma.

Authors:  S Morgello
Journal:  Am J Pathol       Date:  1992-08       Impact factor: 4.307

3.  Transcriptional synergy by the Epstein-Barr virus transactivator ZEBRA.

Authors:  M Carey; J Kolman; D A Katz; L Gradoville; L Barberis; G Miller
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

4.  Sequential use of paraformaldehyde and methanol as optimal conditions for the direct quantification of ZEBRA and rta antigens by flow cytometry.

Authors:  B M Imbert-Marcille; M Coste-Burel; N Robillard; J Foucaud-Gamen; S Billaudel; E Drouet
Journal:  Clin Diagn Lab Immunol       Date:  2000-03

5.  The BFRF1 gene of Epstein-Barr virus encodes a novel protein.

Authors:  A Farina; R Santarelli; R Gonnella; R Bei; R Muraro; G Cardinali; S Uccini; G Ragona; L Frati; A Faggioni; A Angeloni
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

6.  Epstein-Barr viral genome in lymph nodes from patients with Hodgkin's disease may not be specific to Reed-Sternberg cells.

Authors:  A Masih; D Weisenburger; M Duggan; J Armitage; R Bashir; D Mitchell; R Wickert; D T Purtilo
Journal:  Am J Pathol       Date:  1991-07       Impact factor: 4.307

7.  Abundant expression of EBER1 small nuclear RNA in nasopharyngeal carcinoma. A morphologically distinctive target for detection of Epstein-Barr virus in formalin-fixed paraffin-embedded carcinoma specimens.

Authors:  T C Wu; R B Mann; J I Epstein; E MacMahon; W A Lee; P Charache; S D Hayward; R J Kurman; G S Hayward; R F Ambinder
Journal:  Am J Pathol       Date:  1991-06       Impact factor: 4.307

8.  The systemic distribution of Epstein-Barr virus genomes in fatal post-transplantation lymphoproliferative disorders. An in situ hybridization study.

Authors:  P S Randhawa; R Jaffe; A J Demetris; M Nalesnik; T E Starzl; Y Y Chen; L M Weiss
Journal:  Am J Pathol       Date:  1991-04       Impact factor: 4.307

9.  Alterations of the p53 gene in Epstein-Barr virus-associated immunodeficiency-related lymphomas.

Authors:  R H Edwards; N Raab-Traub
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

10.  Epstein-Barr virus activates beta-catenin in type III latently infected B lymphocyte lines: association with deubiquitinating enzymes.

Authors:  Julia Shackelford; Christopher Maier; Joseph S Pagano
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-08       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.